Sanofi Logo
  • For Healthcare Professionals
  • Prescribing Information
  • For U.S. Residents Only
Mozobil logo
  • About Stem Cell Transplants
    • Stem Cell Mobilization
  • Benefits and Risks of Mozobil
  • Support
    • Glossary
  • For Healthcare Professionals
  • Prescribing Information
  1. Home
  2. Site map

Sitemap

  • Home
    • About Stem Cell Transplants
    • Stem Cell Mobilization
    • Benefits and Risks of Mozobil
    • Support
    • Glossary

Important Safety Information for Mozobil (plerixafor) injection

  • Severe, life-threatening allergic reactions (anaphylaxis) can happen in people who take Mozobil. Tell your doctor right away if you experience hives (itchy raised bumps), eye swelling, or trouble breathing.
  • Mozobil is not intended for hematopoietic stem cell transplantation (HSCT) mobilization and collection in patients with leukemia.
  • Mozobil in combination with G-CSF increases circulating white blood cells (WBCs). Your WBC counts will be monitored.
  • Thrombocytopenia (a decrease in the number of platelets circulating in the blood) has been observed in patients receiving Mozobil. Your platelet counts will be monitored.
  • Cancer cells may be released from the bone marrow and subsequently collected along with your stem cells during apheresis. The potential effects of infusing cancer cells during your transplant have not been well-studied.
  • Your spleen may be examined if you experience pain in the left upper stomach area or left shoulder area as these may be signs of an enlarged or burst (ruptured) spleen.
  • Mozobil can harm the unborn child when administered to a pregnant woman. Scientific studies have shown that Mozobil causes harm or death to unborn animals. If you are pregnant, your doctor should tell you about the potential risk to the fetus. If you are a female of childbearing potential you should use an effective form of contraception during treatment with Mozobil and for one week after the final dose.
  • Breastfeeding is not recommended during treatment with Mozobil and for one week after the final dose.
  • The most common adverse reactions (occurring in greater than or equal to 10% of patients) during HSC mobilization and apheresis were: diarrhea (37%), nausea (34%), tiredness (fatigue) (27%), injection site reactions (34%), headache (22%), pain in your joints (arthralgia) (13%), dizziness (11%), and vomiting (10%).

Indication

Mozobil (plerixafor) injection is indicated in combination with granulocyte-colony stimulating factor (G-CSF) to mobilize hematopoietic stem cells (HSCs) to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin’s lymphoma (NHL) or multiple myeloma (MM).

Site map


© 2022 sanofi-aventis U.S. LLC. All rights reserved.

Legal Disclaimer | Privacy Policy | Contact Sanofi

This site is intended for use by U.S. residents only.

This information is intended for U.S. Healthcare Professionals.

"Continue" will take you to the requested page;
"Cancel" will return you to the previous page

You are about to leave
a Sanofi U.S. website

Sanofi U.S. does not review the information contained on this website and/or database for content, accuracy, or completeness. Use of and access to this information is subject to the terms, limitations, and conditions set by the website and/or database producer.

Sanofi U.S. makes no representation as to the accuracy or any other aspect of the information contained on such website and/or database, nor does Sanofi U.S. necessarily endorse such a website and/or

You are about to leave sanofi site for U.S.

Sanofi US does not review the information contained on this website and/or database for content, accuracy or completeness. Use of and access to this information is subject to the terms, limitations and conditions set by the website and/or database producer.

This site might not comply with the regulatory requirements of US

You are about to move to an Unbranded site

You are moving to an Unbranded site

Share this information with friends and family.

E-mail This Page to a Friend

Your friend has shared this page about WhiteSite

Send a copy to myself (optional)
Your Email Has Been Sent

Your email has been sent to:





MAT-US-2012601-v2.0-11/2022